PMID- 18971577
OWN - NLM
STAT- MEDLINE
DCOM- 20090615
LR  - 20191210
IS  - 1421-9832 (Electronic)
IS  - 1018-8665 (Linking)
VI  - 218
IP  - 2
DP  - 2009
TI  - Efficacy of short-term cyclosporine treatment to control psoriasis-related events 
      during efalizumab therapy.
PG  - 146-50
LID - 10.1159/000168086 [doi]
AB  - Efalizumab is a recombinant humanized anti-CD11a monoclonal antibody that blocks 
      the activation, adhesion and trafficking of T cells and has been approved for the 
      treatment of moderate-to-severe plaque psoriasis. To document management of the 
      fluctuations in symptom control that patients with psoriasis sometimes experience 
      during treatment, we performed a retrospective analysis of our experience using 
      cyclosporine as an intercurrent treatment to control psoriasis-related adverse 
      events (AEs) in 10 patients who had received continuous efalizumab therapy for 
      20-200 weeks prior to recurrence of symptoms. Combination therapy with 
      cyclosporine and efalizumab was generally well tolerated and controlled the 
      relapse effectively. There were no reports of severe AEs during combination 
      treatment, and no clinically significant changes were noted in clinical and 
      laboratory values. Although mild, localized psoriasis recurred in most of these 
      patients after cyclosporine termination, no patient experienced rebound or 
      psoriasis flare and all continued with long-term efalizumab treatment.
CI  - Copyright (c) 2008 S. Karger AG, Basel.
FAU - Costanzo, Antonio
AU  - Costanzo A
AD  - Department of Dermatology, University of Rome Tor Vergata, Viale Oxford 81, Rome, 
      Italy. antonio.costanzo@uniroma2.it
FAU - Talamonti, Marina
AU  - Talamonti M
FAU - Spallone, Giulia
AU  - Spallone G
FAU - Botti, Elisabetta
AU  - Botti E
FAU - Chimenti, Maria Sole
AU  - Chimenti MS
FAU - Papoutsaki, Marina
AU  - Papoutsaki M
FAU - Chimenti, Sergio
AU  - Chimenti S
LA  - eng
PT  - Journal Article
DEP - 20081030
PL  - Switzerland
TA  - Dermatology
JT  - Dermatology (Basel, Switzerland)
JID - 9203244
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (CD11 Antigens)
RN  - 0 (Cyclosporins)
RN  - 0 (Immunosuppressive Agents)
RN  - XX2MN88N5D (efalizumab)
SB  - IM
MH  - Adult
MH  - Antibodies, Monoclonal/*therapeutic use
MH  - Antibodies, Monoclonal, Humanized
MH  - CD11 Antigens/*immunology
MH  - Cyclosporins/*therapeutic use
MH  - Drug Therapy, Combination
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Immunosuppressive Agents/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Psoriasis/*drug therapy
MH  - Retrospective Studies
MH  - Time Factors
MH  - Treatment Outcome
EDAT- 2008/10/31 09:00
MHDA- 2009/06/16 09:00
CRDT- 2008/10/31 09:00
PHST- 2008/06/09 00:00 [received]
PHST- 2008/06/30 00:00 [accepted]
PHST- 2008/10/31 09:00 [pubmed]
PHST- 2009/06/16 09:00 [medline]
PHST- 2008/10/31 09:00 [entrez]
AID - 000168086 [pii]
AID - 10.1159/000168086 [doi]
PST - ppublish
SO  - Dermatology. 2009;218(2):146-50. doi: 10.1159/000168086. Epub 2008 Oct 30.